WO1991001760A1 - Human tumor cells implanted in non-human animals - Google Patents
Human tumor cells implanted in non-human animals Download PDFInfo
- Publication number
- WO1991001760A1 WO1991001760A1 PCT/US1990/004344 US9004344W WO9101760A1 WO 1991001760 A1 WO1991001760 A1 WO 1991001760A1 US 9004344 W US9004344 W US 9004344W WO 9101760 A1 WO9101760 A1 WO 9101760A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- support
- cancer cells
- cells
- human animal
- Prior art date
Links
- 210000004881 tumor cell Anatomy 0.000 title claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 54
- 201000011510 cancer Diseases 0.000 claims abstract description 41
- 210000000987 immune system Anatomy 0.000 claims abstract description 16
- 230000008512 biological response Effects 0.000 claims abstract description 15
- 239000003607 modifier Substances 0.000 claims abstract description 13
- 238000010171 animal model Methods 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 238000012360 testing method Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 45
- 230000008569 process Effects 0.000 claims description 35
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 19
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 19
- 210000002744 extracellular matrix Anatomy 0.000 claims description 19
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 18
- 239000003102 growth factor Substances 0.000 claims description 17
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- 230000002491 angiogenic effect Effects 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- -1 polytetrafluoroethylene Polymers 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 4
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 claims 2
- 101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 claims 2
- 239000004810 polytetrafluoroethylene Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 8
- 239000007943 implant Substances 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000012010 growth Effects 0.000 description 12
- 206010029113 Neovascularisation Diseases 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 6
- 239000000367 immunologic factor Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000003200 peritoneal cavity Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 108010022901 Heparin Lyase Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000143637 Eleocharis confervoides Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 2
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 201000010878 atypical lipomatous tumor Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 108700004203 eye-derived growth factor Proteins 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 108010063968 hypothalamus-derived growth factor Proteins 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000005033 mesothelial cell Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 208000022752 well-differentiated liposarcoma Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008883 metastatic behaviour Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
Definitions
- the non-human animal which includes human cancer cells in accordance with an embodiment as hereinabove described, is employed as an animal model for studying the effect of a cancer treatment or therapy.
- the human cancer cells as preferably maintained in a non-human animal on an implanted biocompatible support which may include BRM's, a factor or factors to induce angiogenesis and cell growth.
- This implant is sometimes hereinafter referred to as a neovascularization device.
- Expanded polytetrafluorethylene has been found to be a particularly suitable non-absorbable support. This support provides the following benefits.
- PTFE has a general lack of an inflammatory response which is the basis for the current acceptance of PTFE in the surgical community.
- PTFE can be coated conveniently with extracellular matrix components which can absorb a biological response modifier.
- Biologically active HBGF-I and HBGF-2 can be immobilized to collagen-coated PTFE by previously established methods.
- PTFE polymers are routinely engineered to various specifications to meet a multitude of required configurations.
- mice were maintained on a normal diet and 12 hour light/dark cycle.
- post implant (18,28,35 and 38 days) the mice were killed and then subjected to whole body pressure perfusion with glutaraldehyde, buffered with phosphate, using a catheter inserted into the thoracic aorta.
- the implants were examined macroscopically for blood vessel formation and the internal organ block removed and thin sections through the entire organ block containing the implant device were prepared for histological examination.
- Primary tumor samples are obtained as biopsy samples from human patients.
- human bone marrow can be introduced into the BNX mice by published procedures (see references earlier), as a bone marrow transplant, to establish a patient's bone marrow in the immune deficient mouse. Then tumor cells can be implanted, as described above, and a variety of additional cancer therapies, including the adoptive immunotherapy approach, can be tested. These include LAK cell therapy, TIL cell therapy and ALT therapy. Survival of tumor cells is monitored as described above. The adoptive immunotherapy procedures of LAK, TIL or ALT can be tested with the patients immune cells alone, or in a mouse where the patient's own bone marrow has been reconstituted into the mouse.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A non-human animal model is provided with human cancer cells supported on a support including a biological response modifier, with the animal preferably being immunodeficient with respect to its own immune system. The animal model can also be provided with a human immune system. The model can be used for testing cancer treatment for primary human cancer cells.
Description
- I -
HUMAN TUMOR CELLS IMPLANTED IN NON-HUMAN ANIMALS
This invention relates to tumorigenesis and more particularly to maintaining and testing human cancer cells in non-human animals.
While some tumor cells can be readily grown in culture, they do not, in the environment of the tissue culture vessel, maintain the identical properties of the primary tumor. In fact, they may frequently represent a subtype or selected subpopulation of the primary tumor. Although the property of continuous, and non-contact inhibited growth may persist, numerous other characteristics, including the genes expressed, the nature and quantity of the markers expressed on the cell surface, and the response to hormones, biological response modifiers and other growth factors may be highly variable, and different from the primary tumor of origin.
There exist certain animal models for the maintenance and propagation of tumor cells. In mice, for example, tumor cell models exist, where injection or transplantation of cells will result in tumor development. However, such tumor cells have undergone significant changes from the original primary tumor cells, in becoming adapted to propagation in animals. In addition, it is not a
certain or straight forward process to generate such transplantable tumor cells lines, since only a fraction of primary tumor cells will have the ability to be adapted in this way.
The difficulties are even greater if one attempts to cross species barriers in such transplantable tumor cells. Human tumor cells, for example, will normally succumb to the immune system of mice. One way that has been developed to overcome this, in certain circumstances for certain human tumors, is use of the 'nude' mouse strain (S.P.Flanagan, Genet. Res. Camb. (1966), 8, 295-309. ""Nude," a new hairless gene with pleiotropic effects in the mouse."). In these mice, defects in the immune system allow the survival of certain foreign cells injected or transplanted into the animal. However, even here only a variable fraction of primary human tumors can be successfully propagated.
Thus, there is a need for effective maintenance and propagation of primary human tumor cells in an animal model.
In accordance with an aspect of the present invention, human cancer cells are administered to, and maintained in, a non-human animal wherein the non-human animal is immunodeficient.
In accordance with a preferred embodiment of such aspect of the present invention, the human cancer cells are maintained in the non-human animal which is immunodeficient with respect to its own immune system, on a biocompatible support which may include a growth factor or factors for inducing angiogenesis to the implant, and which may be required for the growth of the cancer cells. (Biological Response Modifiers, or BRMs. )
In accordance with another aspect of the present invention, human cancer cells are maintained in a non-human animal on a biocompatible support which may include such angiogenic or growth factors (BRM's). The non-human animal may or may not be an immunodeficient animal.
In accordance with a further aspect of the present invention, the non-human animal which includes human cancer cells, in accordance with an embodiment as hereinabove described, is employed as an animal model for studying the effect of a cancer treatment or therapy.
In accordance with a further embodiment of the present invention, a non-human animal which includes human cancer cells in accordance with an embodiment as hereinabove described, further includes a human immune system, in particular the animal is provided with human hematopoietic cells which create a human immune system in the non-human animal.
The non-human animal is preferably a rodent.
As hereinabove indicated, the human cancer cells as preferably maintained in a non-human animal on an implanted biocompatible support which may include BRM's, a factor or factors to induce angiogenesis and cell growth. This implant is sometimes hereinafter referred to as a neovascularization device.
The biocompatible support may be a biodegradable support (sometimes referred to herein as an absorbable support) or a nonbiodegradable support (sometimes referred to herein as a nonabsorbable support), preferably a non-biodegradable support.
The neovascularization device or devices can also include in addition to a biological response modifier an extracellular matrix component or components. The support may be formed from an
extracellular protein or the extra-cellular matrix component may be added to the support. For example, the support may be formed from collagen which is an extracellular protein or an extracellular component may be added to the support.
A biological response modifier (BRM) is a biochemical agent that directly or indirectly induces a change in gene expression at the cellular level. Growth hormones and their chimeric derivatives serve as examples of a direct BRM; initiating a biological response ultimately directed to the nucleus and mediated by a specific high affinity receptor. Hydrolases (plasminogen activators, collagenases, heparinase) serve as an example of an indirect BRM; initiating a biological response by enzymatically activating or releasing latent, stored or zymogen precursors of direct BRMs. The BRM may stimulate or facilitate vascular growth from a tissue or organ, and may be required for growth of cells on the support.
Biological response modifiers used on the support can be angiogenic growth factors such as HBGF-I, HBGF-II, platelet-derived growth factor (PDGF), macrophage-derived growth factor (MDGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), hypothalamus-derived growth factor (HDGF), retina-derived growth factor (RDGF), and mixtures thereof. A preferred embodiment of the invention for inducing angiogenesis uses HBGF-I. Desirable hydrolases include a member selected for the group consisting of heparinase, collagenase, plasmin, a plasminogen activator, thrombin, heparinase, and mixtures thereof. Hormones such as the growth factors are particularly desirable as
biological response modifiers. Hormones specifically elicit cell growth and differentiation.
The neovascularization product can also include an extracellular matrix component, which may be the material from which the support is formed or may be added to the support. Although applicant does not intend to be bound by theoretical reasoning, it is believed that the inclusion of the extracellular matrix component may, among other functions, function to hold and to protect the BRM which is included in the product; i.e., provides for adsorption and adherence of the BRM to the support and possibly protects against degradation of the BRM. In addition, the extracellular matrix component may function to absorb cells which participate in the neovascularization or tumor cells added to the device. One or more extracellular matrix components, which may be used alone or in combination, include collagens, laminins, fibronectins, gelatins, glycosaminoglycans, glycoproteins, proteoglycans, and mixtures thereof. The most desirable extracellular matrix components include gelatins and collagens. A preferred embodiment uses collagen Type IV. Collagen Type IV is desirable because it provides desirable adsorption characteristics for the biological response modifier.
The support may be either an absorbable (biodegradable) support or non-absorbable (non-biodegradable) support and the support can be formed from a extracellular matrix component. The preferred support is a non-absorbable support which includes at least one extracellular matrix component to which at least one BRM may be absorbed. Examples of absorbable supports include members of the group consisting of collagen Type I, known commercially by
the trade name "Gelfoam", laminin,' fibronectins , gelatin, glycosaminoglycan, glycolipids, proteolipids, mucopolysaccharides and mixtures thereof. Examples of non-absorbable matrices include members of the group consisting of nylon, rayon, dacron, polypropylene, polyethylene, polyurethane, expanded polytetrafluorethylene (PTFE), cross-linked collage Type IV, and mixtures thereof.
The support is one which is biocompatible with the host in which it is to be implanted and has the rigidity and strength to support growth of the added cells.
Expanded polytetrafluorethylene (PTFE) has been found to be a particularly suitable non-absorbable support. This support provides the following benefits. PTFE has a general lack of an inflammatory response which is the basis for the current acceptance of PTFE in the surgical community. PTFE can be coated conveniently with extracellular matrix components which can absorb a biological response modifier. Biologically active HBGF-I and HBGF-2 can be immobilized to collagen-coated PTFE by previously established methods. PTFE polymers are routinely engineered to various specifications to meet a multitude of required configurations.
Non-woven multifilament angel-hair fibers of expanded PTFE are commercially available from W. L. Gore and Associates, Inc., Flagstaff, Arizona and are particularly suitable as a support. These fibers allow sufficient organized area for infiltrating cells to be exposed to the environment of the host. This permits the free exchange of nutrients and toxic waste to occur while neovascularization processes occur.
Supports can be provided for use in this invention in any desired shape and size. Desirable shapes for a support can be a strip, a sponge, or a tube. Supports are desirably capable of being secured within an organism. Suitable means for securing a support can include a staple, biocompatible glue, or other surgical procedures such as suturing or tying the support to a tissue.
A desirable support is obtained by filing a tube or sleeve of expanded PTFE with expanded PTFE fibers or "angel hair".
For example, HBGF-I is known to bind to components of the extracellular matrix and components of the extracellular matrix can either be immobilized on solid supports or denatured and formed into an insoluble matrix. HBGF-I, adsorbed to either denatured collagen I sponges, or to fibers of expanded PTFE coated with either fibroneotin, collagen I or collagen IV, or to combinations of denatured sponges wrapped with PTFE fibers, promotes angiogenesis in both the normal and immune compromised (BNX) mouse at concentrations which are consistent with the growth, see below factor's activity as a cellular mitogen in vitro.
The most effective concentrations for a biological response modifiers can be a concentration that elicits a growth response from the target cells, but is not toxic to those cells. Effective or therapeutic concentrations of angiogenic growth factors are between about 1 to 100 nanograms per cubic millimeter of a support. A support for this calculation includes both the absorbable support and the non-absorbable support.
In accordance with an aspect of the present invention, a device of the type hereinabove described is seeded with human cancer cells prior or subsequent to implantation of the device in a non-human animal.
The non-human animals which are provided with the human cancer cells are preferably immunodeficient non-human animals; in particular immunodeficient mice and rats. Such immunodeficient mice are known in the art and may for example be SCID mice or mice of the beige/nu/Xid, (BNX) genotype, [McCune S.M., Namikawa R. , Kaneshima H. , Shultz L. D. , Liberman M. , Weissman IL: The "SCIDHu Mouse: Murine Model for the Analysis of Human Hematolymphoid Differentiation and Function" Science 241: 1632-1639 (1988). Mosier D.E., Gulizia R.J. , Baird S.M., Wilson D.B.: "Transfer of a Functional Immune System to mice with Severe Combined Immunodeficiency". Nature 335: 256-259 (1988). Kamel-Reid, S. and Dick, J.E.: Engraftment of Immune-Deficient mice with Human Hematopoietic stem cells, Science 242: 1708-1709 (1988)] and which have little immune function left to interfere with the growth of foreign cells. These mice have been extensively used for human tumor xenografts (Isaiah J. Fidler, Cancer and Metastasis Review, 5:29-49 (1986), "Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis"; Seiji Naito, et_ al. , Clin. Expl. fletastasis, vol. 5, #2, 135-146, (1987), "Growth and metastatic behavior of human tumor cells implanted into nude and beige nude mice,"; Jurgen Mattern, et al.. Cancer and Metastasis Reviews, 7:263-284, (1988), "Human tumor xenografts as model for drug testing,"; Andrew Pawlowski and Peter J. Lea, in Skin Tumore: Experimental and Clinical Aspects, edited by Claudio J. Conti, et al. , Raven
Press, New York, (1989), "Human Melanoma Xenografts". ).
Although in a preferred embodiment, the human cancer cells are placed on a neovascularization device of the type described in an immunodeficient non-human animal, it is possible within the spirit and scope of the invention to use a non-immunodeficient non-human animal.
In accordance with another embodiment of the invention, the immune deficient non-human animal, in particular mice, are provided with other human cells in addition to the primary human cancer cells. First, these may be precursor cells that will provide the animal with a human immune system. This kind of device allows testing of cellular and biological procedures for arresting tumor cell growth or for tumor destruction. In particular, examples are adoptive immunotherapy procedures such as LAK therapy (Rosenberg,S.A. , J.N.C.I. 75, 595-603, 1985; Mule, J.J., et al.. Science 225, 1487-9, 1984) or TIL cell therapy (Rosenberg, S.A., et al.. New Engl.J.Med. 319. 1676-80; Rosenberg, S,A., et al.. Science 223. 1318-21, 1986.), or any agents capable, on administration, of stimulating the newly generated immune system in the mouse to arrest the growth of, or kill the tumor cells in, the implant. This system is used in an autologous fashion e.g. , the immune system of a patient is duplicated in the immune deficient mice, while tumor cells are implanted via the implant, and then the particular therapies applied.
Second, other cells in addition to the tumor cells may be applied in the implant. These could be any of a wide variety of cells known to be able to grow on such an implant system, and may include, but
not be limited to, fibroblasts, smooth muscle cells, endothelial cells, epithelial cells, hepatocytes, mesothelial cells. Such cells may function to support tumor cell growth by a variety of mechanisms eg by secretion of particular growth factors, angiogenic factors, extracellular matrix components, or other factors, all of which may constitute the appropriate micro environment for maintenance of the properties and growth of the primary tumor cells. Additionally, cells may be added and screened for the property of production of agents, or other properties of inhibition of the growth of tumor cells which usually grow well on the support without additional cells.
The human cancer cells which are used in the present invention are so-called primary human cancer cells (i.e., cells taken directly from a patient's tumor and maintained .in vitro only for the shortest possible time). The cancer cells may include, but are not limited to the following types; breast, lung, ovarian, melanoma, colorectal, renal.
Thus, in accordance with an aspect of the present invention, human cancer cells are placed in a non-human animal in an .in vivo physiological environment that maintains the appropriate properties and characteristics of the original human primary cancer cells. In this manner, such human cancer cells may be tested and/or studied and/or treated in a non-human animal model under in vivo conditions which do not alter the characteristics of the cancer cells.
Thus, the present invention can provide a non-human animal model system for testing, studying, manipulating and predicting behavior of tumor cells
and developing treatments for primary human tumor cell lines from a variety of different cancers.
In accordance with the present invention, the properties of cells of an individual human patient may be developed in the animal model and be used to predict the growth and behavior of such cells in the patien .
In addition, a patient's tumor cells may be established in a number of different non-human animals and such animals may be subjected to a variety of therapeutic procedures (singly or in combination; chemical and/or physical) to thereby determine the best course of treatment.
The invention will be further described with respect to the following examples; however, the scope of the invention is not to be limited thereby;
Exaaple I General Procedure for Implanting in BNX Mice
The abdomen of an anesthetized mouse was washed with 20 percent ethanol and an incision was made into the abdominal wall to expose the peritoneal cavity. Gelfoam (Upjohn, Kalamazoo, Michigan), cut into strips of approximately 20x15x7mm, or expanded PTFE fibers (W. L. Gore, Inc., Flagstaff, Arizona) pre-coated with collagen IV and pre-weighed (0.2gm dry weight), or a combination of these two materials (Gelfoam strips wrapped with PTFE fibers) were treated with approximately 0.5 ug of HBGF-I in 100 ml of water at 4°C for one hour. Following adsorption of the growth factor the constructed implant device was placed adjacent to the liver of the mouse. The surgical opening was closed by suture or staple gun and the mice were maintained on a normal diet and 12 hour light/dark cycle. At various times post implant (18,28,35 and 38 days) the mice were killed and then
subjected to whole body pressure perfusion with glutaraldehyde, buffered with phosphate, using a catheter inserted into the thoracic aorta. The implants were examined macroscopically for blood vessel formation and the internal organ block removed and thin sections through the entire organ block containing the implant device were prepared for histological examination.
A significant angiogenic response was observed macroscopically and microscopically within 18 days after surgery in all mice (normal (C57) and immune compromised (BNX) mice) treated with HBGFI. Blood vessels, at the tissue site of implantation, were observed macroscopically to be exclusively within the implant. Control implants without HBGF-I did not induce neovascularization. Histological examination of the implants revealed new blood vessel growth within the implants. Total numbers of mice analyzed in this experiment were 3 for C57, and 18 for BNX.
After as long as 40 days, the implants were examined for the extent of angiogenesis. Bidirectional formation of new blood vessels along the HBGF-I implant from the liver and other tissue sites were observed. Further examination revealed that the implant contained vascular "strings" which connected the implant to the existing vascular tree. The ability of HBGF-I implants to maintain these neovessel structures within the peritoneum is evidenced by these highly vascular bridges. Histological examination of these long term implants displayed a large organized solid matrix surrounded by a collagenous capsule (scar) and containing a network of neovessel formations interdigitated with different cell types. Histological examinations
(longitudinal and cross-section) through typical vascular "strings" revealed the presence of a monolayer of mesothelial cells surrounding a large vascular lumina in the central portion, encompassed by prominent endothelial cells and multiple layers of smooth muscle cells, representing mature and highly differentiated arterioles. Within the periphery are abundant capillary lumina, and the entire vascular bundle is surrounded by a continuous fibrσcellular capsule. Further examination of this sample at high magnification revealed the relatively rich collagen component of vascular structure as well as the abundance of endothelial cell-line capillary structures.
In accordance with the device and method of the present invention, angiogenesis and neovascularization has been achieved in the peritoneal cavity of the immune-compromised mouse (BNX).
Exaβple 2
Example 2 demonstrates that the presence of a large vascularized, organized solid matrix, which contains a network of neovessel formations, contiguous with the BNX mouse vascular tree, permits successful transplantation of either a rat-derived hepatoma cell line or a human-derived melanoma cell line into a BNX mouse.
The diploid cell strain, RL-PR-C, a minimally deviated rat hepatoma cell line, and a cell line, A375, derived from a human melanoma, were maintained in culture with either RPMI 1640 (RL-PRC) or high
glucose defined minimal essential media with 10% fetal calf serum, 0.03M glutamine and gentamicin (0.5 mg/ml). These cells were plated on 100mm tissue culture plates and maintained in culture with medium changed every two (2) days for the duration of the experimen .
In order to identify and characterize these tumor cells during the transplantation process, cells were transduced with recombinant retroviral vectors. Either N2 or LNL6 (Armeninano, D. , et al.. J. Virology 6J., 1657-1650; Adam, A.M., and Miller, A.D. (1988) J. Virol. .62, 3802-3806) was used to transfer and integrate the gene for neomycin resistance (Neoβ) into the host genomic sequences. Both of the retroviral vectors used in this example are Moloney murine leukemia virus-based vectors with the viral coding sequences removed and the Neo-resistance gene from the bacterial Tn5 transposon inserted. A clone producing a high titer of amphotropic virus containing either N2 or LNL6 was isolated by G418 selection of the helper-free packaging cell line PA317 after calcium phosphate-mediated DNA transfection of the appropriate viral plasmids. Virus-containing supernatants were collected from a confluent monolayer in Dulbecco's minimal essential medium containing 10% fetal calf serum. Following filtration, the viral supernatants were stored at -70°C until used.
Cultured monolayers of either PL-PR-C cells or A375 cells (2x10 ) were exposed to virus containing supernatants containing virus particles (2x10 ), polybrene (8ug/ml) and appropriate culture medium for 2 hours at 37°C. Following exposure, fresh culture
medium was added and cells were cultured for 48 hours at 37°C. Infected cells, both RL-PR-C (Neo®) and A375 (Neo®) were exposed to G418 (800uq/ml) for two weeks whereupon transduced colonies were expanded for subsequent transplantation.
Transduced tumor cells, RL-PR-C (Neo®) or A375 (Neo®) were grown to high density (1x10 ) on Gelfoam sponges (15x12x7mm) and wrapped with 0.2gm of expanded PTFE fibers previously coated with collagen IV and containing adsorbed HBGF-I (0.5ug). This device was surgically implanted in the peritoneal cavity adjacent to the liver of BNX mice as previously described.
At various times post implantation, wrapped sponges were surgically removed and washed extensively in phosphate buffered saline (PBS). Washed implants were digested 30 to 60 minutes at 37°C with a solution of collagenase in PBS (lmg/ml) in a tissue culture incubator (5% C02). Released cells were collected by centrifugation (10 min, 2000 x g, 20°C) and washed once with PBS and pelleted by centrifugation. Cells were resuspended with appropriate tissue culture medium containing G418 (800ug/ml) and plated for 16 hours on 100mm tissue culture flasks. Plated cells were washed with PBS extensively and fed fresh medium. Medium was changed every two days for the duration of the procedures. Large numbers of viable RL-PR-C (Neo®) cells were recovered at 18, 25 and 34 days post implantation as evidenced by their ability to grow in the presence of G418. This observation was further confirmed by a direct assay of the neomycin phosphotransferase activity (the direct product of the Neo® gene).
Viable A375 (Neo®) cells were recovered at 27, 34 and 40 days post implantation which both grew in the presence of G418 as well as displayed positive neomycin phosphotransferase activity.
Induced neovascularization within the peritoneal cavity has therefore been shown to sustain the proliferative potential of tumor cells simultaneously implanted with HBGF-1 adsorbed solid supports. Tumor cells which were recovered from these HBGF-I implants were able to proliferate .in vitro under selective pressure which reflects their genetic disposition.
Exaaple 3
Primary Tumor Cells on Implants in BNX Mice
Primary tumor samples are obtained as biopsy samples from human patients.
These tumor cells, purified from immune system cells if necessary, by standard cell-separation procedures or as pieces of intact tumor, are maintained for a minimal period in vitro in an appropriate medium prior to seeding onto the support for an implant, as described in Examples 1 and 2. The cells on the support are implanted into BNX mice as previously described or as 0.25 to 0.5 cubic centimeter chunks wrapped in 0.1 gm fibers coated with collagen I and 0.25 μg HBGF-1, and a time course of survival of the cells in the implant is carried out. The implant is placed in the peritoneal cavity. Survival and growth of the cells is monitored biochemically, by isolation DNA from cells in the implant, and molecular hybridization with human-specific repetitive sequence DNA probes. Monitoring is also by immunσhistochemical means, using implant sections and immune antisera specific
for human and/or tumor cell specific surface markers. Finally, mouse serum can be screened for any human and/or tumor specific secretion products made by cells on the implant and secreted into the circulation.
Having established primary human tumor cells on implants in a series of BNX mice, various therapeutic modalities can be tested to see which are most effective in killing of the patient's tumor cells in vivo in the mouse. The treatments can be but are not limited to regular chemotherapy with established agents, radiation therapy, treatment with biological response modifiers and antitumor agents such as tumor necrosis factor, interleukin 2, σ interferon, interferon, interleukin 1, interleukin 4, or a wide range of other such agents.
Response to therapy can be monitored in several ways. Most simple and effective is to monitor a decrease in production and appearance in the mouse's circulation of tumor specific products. Also, the implants can be examined biochemically and histologically to determine the survival of the tumor cells.
Additionally, human bone marrow can be introduced into the BNX mice by published procedures (see references earlier), as a bone marrow transplant, to establish a patient's bone marrow in the immune deficient mouse. Then tumor cells can be implanted, as described above, and a variety of additional cancer therapies, including the adoptive immunotherapy approach, can be tested. These include LAK cell therapy, TIL cell therapy and ALT therapy. Survival of tumor cells is monitored as described above. The adoptive immunotherapy procedures of LAK,
TIL or ALT can be tested with the patients immune cells alone, or in a mouse where the patient's own bone marrow has been reconstituted into the mouse.
Number modifications and variations of this invention are possible; therefore, within the scope of the dependent claims, the invention may be practiced otherwise than as particularly described.
Claims
1. A process for producing an animal model containing human cancer cells comprising: providing a non-human animal with a biocompatable support which includes both biological response modifier and human cancer cells.
2. The process of claim 1 wherein the non-human animal is immunodeficient with respect to its own immune system.
3. The process of claim 2 wherein the biological response modifier is an angiogenic growth factor.
4. The process of claim 3 wherein the growth factor is a heparin binding growth factor.
5. The process of claim 2 wherein the support includes an extracellular matrix component.
6. The process of claim 5 wherein the extracellular matrix component is a collagen.
7. The process of claim 2 wherein the support is a non-absorbable support.
8. The process of claim 7 wherein the support is comprised of polytetrafluoroethylene.
9. The process of claim 2 wherein the non-human animal is a beige/nu/Xid mouse.
10. The process of claim 2 wherein the cancer cells are primary tumor cells.
11. The process of claim 10 wherein the biological response modifier is an angiogenic growth factor and the support further includes an extracellular matrix component.
12. The process of claim 2 wherein the non-human animal includes a human immune system.
13. The process of claim 12 wherein the biological response modifier is an angiogenic growth factor.
14. The process of claim 12 wherein the support includes an extraceullar matrix component.
15. The process of claim 12 wherein the support is a nonabsorbable support.
16. The process of claim 12 wherein the non-human animal is a beige/nu/Xid mouse.
17. The process of claim 12 wherein the cancer cells are primary tumor cells.
18. The process of claim 12 wherein the biological response modifier is an angiogenic growth factor and the support further includes an extracellular matrix component.
19. A process for testing a cancer treatment for human cancer cells, comprising: subjecting a non-human animal to a treatment for human cancer cells, said non-human animal including cancer cells, said non-human animal being immunodeficient.
20. A process for testing a cancer treatment for human cancer cells, comprising: subjecting a non-human animal to a treatment for human cancer cells, said non-human animal including a biological response modifier and human cancer cells supported on a biocompatable support.
21. The process of claim 20 wherein the non-human animal is immunodeficient with respect to its own immune system.
22. The process of claim 21 wherein the biological response modifier is an angiogenic growth factor.
23. The process of claim 22 wherein the growth factor is a heparin binding growth factor.
24. The process of claim 21 wherein the support includes an extracellular matrix component.
25. The process of claim 21 wherein the support is a nonabsorbable support.
26. The process of claim 21 wherein the non-human animal is a beige/nu/Xid mouse.
27. The process of claim 21 wherein the cancer cells are primary tumor cells.
28. The process of claim 27 wherein biological response modifier is an angiogenic growth factor and the support further includes an extracellular matrix component.
29. A non-human animal model produced by the process of claim 1.
30. The process of claim 2 wherein the support including the cancer cells is implanted in the non-human animal.
31. The process of claim 2 wherein.the cancer cells are added to a support implanted in the non-human animal.
32. The process of claim 20 wherein the non-human animal includes a human immune system.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38951789A | 1989-08-04 | 1989-08-04 | |
US389,517 | 1989-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991001760A1 true WO1991001760A1 (en) | 1991-02-21 |
Family
ID=23538586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/004344 WO1991001760A1 (en) | 1989-08-04 | 1990-08-02 | Human tumor cells implanted in non-human animals |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2022670A1 (en) |
WO (1) | WO1991001760A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0531733A1 (en) * | 1991-08-12 | 1993-03-17 | Biomaterial Co., Ltd. | Carrier for animal cell culture |
WO1996027657A1 (en) * | 1995-03-03 | 1996-09-12 | Massachusetts Institute Of Technology | Cell growth substrates with tethered cell growth effector molecules |
US6203787B1 (en) | 1997-10-10 | 2001-03-20 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
WO2005086781A2 (en) | 2004-03-05 | 2005-09-22 | Trustees Of The University Of Pennsylvania | Regulatory t cells and their use in immunotherapy and suppression of autoimmune responses |
EP1731030A1 (en) * | 2004-03-04 | 2006-12-13 | Cellseed Inc. | Method of constructing animal having cancer cells transplanted thereinto |
US7175839B1 (en) | 1997-10-10 | 2007-02-13 | Meyer Pharmaceuticals Llc | Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy |
US7361332B2 (en) | 1995-03-17 | 2008-04-22 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
WO2009122443A3 (en) * | 2008-03-31 | 2009-12-23 | Council Of Scientific & Industrial Research | A tumor model system useful to study multistage cancer |
-
1990
- 1990-08-02 WO PCT/US1990/004344 patent/WO1991001760A1/en unknown
- 1990-08-03 CA CA002022670A patent/CA2022670A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 97, issued 1982, (Columbus, Ohio, USA), WARENIUS et al., "In Vivo-In Vitro Clonogenic Assay in a Human Tumor Xenograft with High Plating Efficiency", page 10, Col. 2, Abstract 84,583f; & BRIT. J. CANCER, 1982, 46(1), 45-50, Eng.). * |
CHEMICAL ABSTRACTS, Vol. 98, issued 1983, (Columbus, Ohio, USA), STEEL et al., "The Response to Chemotherapy if a Variety of Human Tumor Xenografts", page 7, Col. 1, Abstract 137,114h ; & BRIT. J. CANCER, 1983, 47(10), 1-13, (Eng.). * |
CHEMICAL ABSTRACTS, Volume 97, issued 1982, (Columbus, Ohio, USA), FUJITA et al., "Characteristic of Human Gastrointestinal and Breast Cancer Xenografts in Nude Mice, with Special Reference to Carcinoembryonic Antigen and Chemosensitivity", page 11. Col. 1, Abstract 155, 831y; & NIPPON GEKA GAKKAI ZASSHI, 1982, 83(5), 457-67, (Japan). * |
CHEMICAL ABSTRACTS, Volume 99, issued 1983, (Columbus, Ohio, USA), INUOE et al., "Antitumor Efficacy of seventeen Anticancer Drugs in Human Breast Cancer Xenograft (MS-1) Transplanted in Nude Mice", see page 9, Col. 2, Abstract 98704z; & CANCER CHEMOTHER. PHARMACOL. 1983, Vol. 10(3), 182-6 (Eng.). * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0531733A1 (en) * | 1991-08-12 | 1993-03-17 | Biomaterial Co., Ltd. | Carrier for animal cell culture |
US7008634B2 (en) | 1995-03-03 | 2006-03-07 | Massachusetts Institute Of Technology | Cell growth substrates with tethered cell growth effector molecules |
US6045818A (en) * | 1995-03-03 | 2000-04-04 | Massachusetts Institute Of Technology | Cell growth substrates with tethered cell growth effector molecules |
US5906828A (en) * | 1995-03-03 | 1999-05-25 | Massachusetts Institute Of Technology | Cell growth substrates with tethered cell growth effector molecules |
WO1996027657A1 (en) * | 1995-03-03 | 1996-09-12 | Massachusetts Institute Of Technology | Cell growth substrates with tethered cell growth effector molecules |
US7361332B2 (en) | 1995-03-17 | 2008-04-22 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
US6203787B1 (en) | 1997-10-10 | 2001-03-20 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
US7175839B1 (en) | 1997-10-10 | 2007-02-13 | Meyer Pharmaceuticals Llc | Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy |
EP1731030A4 (en) * | 2004-03-04 | 2009-11-04 | Cellseed Inc | Method of constructing animal having cancer cells transplanted thereinto |
EP1731030A1 (en) * | 2004-03-04 | 2006-12-13 | Cellseed Inc. | Method of constructing animal having cancer cells transplanted thereinto |
WO2005086781A2 (en) | 2004-03-05 | 2005-09-22 | Trustees Of The University Of Pennsylvania | Regulatory t cells and their use in immunotherapy and suppression of autoimmune responses |
WO2009122443A3 (en) * | 2008-03-31 | 2009-12-23 | Council Of Scientific & Industrial Research | A tumor model system useful to study multistage cancer |
US8563306B2 (en) | 2008-03-31 | 2013-10-22 | Council Of Scientific & Industrial Research | Tumor model system useful to study multistage cancer |
AU2009233322B2 (en) * | 2008-03-31 | 2014-04-17 | Council Of Scientific & Industrial Research | A tumor model system useful to study multistage cancer |
US9131668B2 (en) | 2008-03-31 | 2015-09-15 | Council For Scientific And Industrial Research | Tumor model system useful to study multistage cancer |
Also Published As
Publication number | Publication date |
---|---|
CA2022670A1 (en) | 1991-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6893812B2 (en) | Three-dimensional ex vivo angiogenesis system | |
CN102497871B (en) | Extracellular matrix compositions for the treatment of cancer | |
CN105517587A (en) | Wound healing and tissue engineering | |
EP2981273B1 (en) | Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators | |
JPH10506266A (en) | Growth control of cells encapsulated in bioartificial organs | |
PT91676A (en) | THREE-DIMENSIONAL CELL AND TISSUE CULTURE SYSTEM | |
JPH07508663A (en) | Pre-vascularized polymeric grafts for organ transplantation | |
JPH07102130B2 (en) | Chimeric neomorphogenesis of organs by controlled cell transplantation using artificial matrix | |
CN103937737A (en) | Isolated renal cells and uses thereof | |
Zhao et al. | Nerve regeneration in apseudo-nerve'graft created in a silicone tube | |
Plant et al. | Implantation of collagen IV/poly (2-hydroxyethyl methacrylate) hydrogels containing Schwann cells into the lesioned rat optic tract | |
CN102596182B (en) | Use of biocompatible compositions and materials polymerized therefrom for inhibiting angiogenesis | |
JPH03503167A (en) | Site-directed angioplasty device and its usage | |
JPH09509571A (en) | Method for preparing clonogenic fibroblasts, method for gene transfection of fibroblasts and gene transfection fibroblasts thus obtained | |
KR20200065892A (en) | A composition for bio transplanting of organoid | |
WO1991001760A1 (en) | Human tumor cells implanted in non-human animals | |
JP3404572B2 (en) | Multicellular in vitro assay of angiogenesis | |
US6495364B2 (en) | Mx-1 conditionally immortalized cells | |
KR101561744B1 (en) | 3D cell implant patch and process for preparing the same | |
Reinfeldt Engberg et al. | Expansion of submucosal bladder wall tissue in vitro and in vivo | |
US20090214613A1 (en) | Endothelized Artificial Matrix Comprising a Fibrin Gel, Which Is a Superproducer of Proangiogenic Factors | |
Willacy et al. | A perioperative layered autologous tissue expansion graft for hollow organ repair | |
WO2021176455A1 (en) | Methods of in-ovo screening of anti-cancer therapies | |
Engberg et al. | Research Article Expansion of Submucosal Bladder Wall Tissue In Vitro and In Vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |